Education / Training / Research Opportunities / News
There
are currently available positions for postdoctoral and graduate student
research.
Learn more about the graduate
programs in the Department
of Pharmacology and Cell Biophysics or fill out an online
graduate application.
For further information regarding postdoctoral
research opportunities / training send a copy of your curriculum vitae
in Word format; please email Dr. Kranias at Litsa.Kranias@UC.edu
or write:
Dr. Litsa Kranias
Department of Pharmacology & Cell Biophysics
University of Cincinnati, College of Medicine
231 Albert Sabin Way
Cincinnati, Ohio 45267-0575
News
Date: 4/1/2008
Kranias Named Chair of Pharmacology and Cell Biophysics
Litsa Kranias, PhD, has been named chair of the pharmacology and cell
biophysics department, effective April 1 and pending approval by the UC
Board of Trustees. Kranias, a professor of pharmacology and cell biophysics
and director of cardiovascular biology, has been on the College of Medicine’s
faculty since 1978. She has made significant advances in identifying key
genes associated with heart failure and sudden death. Kranias has also
distinguished herself internationally as a molecular cardiac researcher
and has received continuous funding and recognition from the National
Institutes of Health.
Date: 12/8/2005
Chapel
Hill Startup’s Drug Targets Congestive Heart Failure
A startup focused on a drug to battle congestive heart failure has already
landed $500,000 in seed financing and is hunting for millions more. NanoCor
Therapeutics, a spin-off of Chapel-Hill based Asklepios BioPharmaceutical,
launched operations in November. NanoCor’s lead drug candidate is
called Carfostin. It is designed to combat congestive heart failure and
can be delivered intravenously or via a catheter. Carfostin is based on
research done by three doctors, including Richard Samulski of the University
of North Carolina at Chapel Hill. Also involved are Litsa Kranias of the
University of Cincinnati and Roger Hajjar of Harvard University.
Date: 2/23/2005
NIH
Awards UC $19.8 Million for Heart Failure Study
The $19,871,486 million grant, called a Specialized Center
of Clinically Oriented Research (SCCOR), was awarded over five years by
the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes
of Health (NIH) and will support five projects.
UC researchers leading SCCOR grant projects include Dr.
Dorn, Litsa Kranias, PhD, Stephen Liggett, MD, Jeffery Molkentin, PhD,
and Jeffrey Robbins, PhD. Co-investigators are Harvey Hahn, MD, and Lynne
Wagoner, MD.
Date: 2/22/2005
P&G,
Children's Hospital reach deal for treating heart disease By Tim Bonfield
Enquirer staff writer
Cincinnati Children's Hospital Medical Center and Procter
& Gamble Pharmaceuticals have reached a licensing agreement for a
potential treatment for congestive heart failure, a leading cause of death
from heart disease.
Heart failure is a potentially lethal condition in which the heart muscle
gradually weakens and can no longer pump enough blood to the body. This
may limit tolerance for exercise or may cause fluid retention with swelling
of the feet or shortness of breath. About 5 million people nationwide
have heart failure.
The agreement gives P&G exclusive rights to develop medications based
on an enzyme called protein kinase C alpha, which is involved in heart
failure. The enzyme was discovered by Dr. Jeffery Molkentin, a molecular
biology researcher at Cincinnati Children's, in collaboration with Dr.
Evangelia Kranias, a researcher at the University of Cincinnati
College of Medicine.
In years to come, should a successful medication be developed, the inventors
and Cincinnati Children's stand to collect royalty payments. Precise terms
of the agreement, however, were not disclosed.
Date: 3/7/2003
UC,
Harvard Researchers Link PLN Protein Mutations to Heart Failure
Researchers at the University of Cincinnati and Harvard
have newly published studies showing that mutations of the human PLN gene
are linked to heart failure. The UC research, led by Litsa Kranias,
PhD, professor of pharmacology and cell biophysics, appears in
the February 26 edition of the Journal of Clinical Investigations.
By: Sheryl Hilton
Dean's
List Oct 13, 2003
Date: 5/19/2000
George
B. Rieveschl Jr. Award for Distinguished Scientific Research
Research: Engineering Mice To Fight Heart Disease in Humans
By: Sheryl Hilton
|
